The stage-based analysis showed that C1R (2.34E−04), A2M (3.15E−04), LTBP1 (3.15E−04), SERPING1 (4.23E−04), and BASP1 (4.88E−04) were significantly downregulated only in patients with stage I (early-stage) stomach cancer whereas SERPINB6 (2.0E−03), G0S2 (1.80E−02), HSD17B10 (2.50E−02), ECM1 (2.60E−02), and PRDX1 (2.80E−02) were significantly downregulated in patients with stage III (locally advanced) stomach cancer (Fig. 4D). This evidence concerns the gene SERPING1 and gastric neoplasm.